Analysts Set Alcobra Ltd. (NASDAQ:ADHD) PT at $5.17
Shares of Alcobra Ltd. (NASDAQ:ADHD) have earned an average rating of “Hold” from the eleven brokerages that are presently covering the company. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $5.17.
ADHD has been the topic of several research reports. WBB Securities cut Alcobra from a “hold” rating to a “sell” rating and reduced their target price for the stock from $5.00 to $4.00 in a report on Monday, September 12th. Oppenheimer Holdings Inc. cut Alcobra from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 29th. Jefferies Group reissued a “buy” rating on shares of Alcobra in a research note on Thursday, August 25th. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 price objective on shares of Alcobra in a research note on Wednesday, August 31st. Finally, Goldman Sachs Group Inc. reissued a “buy” rating on shares of Alcobra in a research note on Thursday, September 1st.
Shares of Alcobra (NASDAQ:ADHD) opened at 2.56 on Monday. The company’s 50-day moving average price is $4.34 and its 200 day moving average price is $4.45. Alcobra has a one year low of $1.95 and a one year high of $8.78. The stock’s market capitalization is $70.56 million.
Alcobra (NASDAQ:ADHD) last issued its earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. Analysts anticipate that Alcobra will post ($0.94) EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors boosted its position in Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock worth $1,621,000 after buying an additional 6,516 shares in the last quarter. Stifel Financial Corp boosted its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares in the last quarter. Palo Alto Investors LLC boosted its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares in the last quarter. Jefferies Group LLC acquired a new position in Alcobra during the second quarter worth approximately $533,000. Finally, VHCP Management LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares in the last quarter. 73.69% of the stock is currently owned by hedge funds and other institutional investors.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.